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ABSTRACT
Introduction: Cognitive impairments are common in both Autism
Spectrum Disorders (ASD) and schizophrenia, but it is unclear
whether the pattern of difficulties is similar or different in the two
disorders. This cross-sectional and longitudinal study compared
the neuropsychological functioning in adolescents with ASD with
adolescents with Early Onset Schizophrenia (EOS).
Methods: At baseline and at two-year follow-up, participants were
assessed with a brief neuropsychological test battery measuring
executive functions, visual and verbal learning, delayed recall and
recognition and psychomotor speed.
Results: We found similar levels of neuropsychological impairment
across groups and over time in the adolescents with ASD or EOS.
Adolescents in both groups did not improve significantly on
verbal learning, verbal delayed recall, visual learning, visual
delayed recall or visual delayed recognition, and both groups
performed poorer on verbal recognition. Both groups improved
on measures of psychomotor processing and executive functions.
Conclusion: The findings suggest that it may be difficult to
differentiate adolescents with EOS and ASD based on
neuropsychological task performance. An implication of the results
is that adolescents with either disorder may benefit from a similar
approach to the treatment of cognitive impairment in the disorders.
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Autism Spectrum Disorders (ASD) and schizophrenia are disorders with different ages of
onset, separate presenting characteristics and divergent developmental courses (Konstantareas
& Hewitt, 2001). Nevertheless, both disorders have been conceptualised as neurodevelopmen-
tal disorders with a shared genetic architecture (Fiksinski et al., 2017; Ionita-Laza et al., 2014;
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Lee et al., 2013; Lionel et al., 2013). Increasing evidence suggests that ASD and schizo-
phrenia co-occur at elevated rates. However, the prevalence of ASD in individuals with
schizophrenia is more common than the prevalence of schizophrenia in ASD (Canitano
& Pallagrosi, 2017; Chisholm, Lin, Abu-Akel, & Wood, 2015; Zheng, Zheng, & Zou,
2018). There is evidence of similar grey matter volume reduction in the limbic–striato–
thalamic circuitry in both ASD and schizophrenia (Cheung et al., 2010). In addition,
there are indications of an overlap of clinical symptoms in the two disorders (Spek &
Wouters, 2010; Tordjman, 2008). Impairment in social functioning is one of the
primary features of the clinical presentations in both ASD and schizophrenia (Couture
et al., 2010). Problems with social functioning may be reflected in social withdrawal,
little or no social communication ability or reduced facial or emotional expression and
problems with close personal relationships (Wakabayashi, Baron-Cohen, & Ashwin,
2012). Impairments in social cognition and theory of mind are also common in both
disorders (Lugnegård, Hallerbäck, Hjärthag, & Gillberg, 2013; Tin et al., 2018).
Although there has been an increasing interest in possible connections between ASD
and schizophrenia in the past decade, there have been few studies examining similarities
or differences in neuropsychological functioning between the disorders. Research on
adults with ASD and schizophrenia have found similar deficits in their neuropsychological
functioning, with the largest shared impairment involving speed of processing (Eack et al.,
2013). Further, a recent study found an association between left prefrontal cortex dysfunc-
tion and neuropsychological deficits in both disorders (Pu et al., 2018). Marinopoulou,
Lugnegård, Hallerbäck, Gillberg, and Billstedt (2016) found that adults with schizophrenia
and adults with ASD shared similar neuropsychological profiles. Although their study
revealed that both groups had relatively low working memory and processing speed
scores compared with typically developing controls, full-scale IQ was significantly
higher in the ASD group. In another study involving adults, processing speed was
found to be significantly lower in the patients with schizophrenia compared with the
patients with ASD (de Boer, Spek, & Lobbestael, 2014).
Results from neuropsychological studies on adult patients with ASD or schizophrenia
may not directly apply to children and adolescents with the same disorders, due to the
considerable cognitive development takings place between childhood and adulthood.
Research results on adult patient samples may also be confounded by varying durations
of illness or treatment within the groups that can impact neuropsychological performance.
In addition, social isolation over time can be a confounding factor. Therefore, it is impor-
tant to investigate whether neuropsychological deficits found in adult samples of ASD and
schizophrenia are similar to those present in children and adolescents with the same dis-
orders. Early Onset Schizophrenia (EOS) is often defined as onset before age 18. The life-
time prevalence of schizophrenia is 1% (Perälä et al., 2007). The prevalence of EOS is
about 0.2%–0.5% (Excellence, 2013). EOS has been associated with a more severe clinical
course than adult onset schizophrenia (Oie, Sundet, & Ueland, 2011). In 2012, the global
prevalence of ASD was estimated by the World Health Organization to be 1% (Elsabbagh
et al., 2012). A better understanding of the differences or similarities in neuropsychological
functioning in children and adolescents with ASD or EOS would allow for cognitive inter-
ventions to be applied earlier and on a more evidence-based foundation.
Several cross-sectional studies have focussed on neuropsychological functioning in chil-
dren and adolescents with ASD or EOS compared to typically developing (TD) controls.
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In children with ASD, significant impairments have been documented in executive
functioning (Demetriou et al., 2017; Hill, 2004; Lai et al., 2017) and memory performance
(Williams, Goldstein, & Minshew, 2006). Some studies have also indicated a working
memory developmental delay in longitudinal studies of children with ASD (Andersen,
Hovik, Skogli, Egeland, & Oie, 2013; Andersen, Skogli, Hovik, Geurts, et al., 2015;
Luna, Doll, Hegedus, Minshew, & Sweeney, 2007; O’Hearn, Asato, Ordaz, & Luna,
2008). Other longitudinal studies have found persistent mental flexibility and response
inhibition impairments in children with ASD compared with TD controls (Geurts, van
den Bergh, & Ruzzano, 2014; Pellicano, 2010).
In a review of cross-sectional studies of neuropsychological functioning in individuals
with EOS, Frangou (2010) found impairments of medium to large effect sizes in IQ, atten-
tion, memory and executive functions compared with TD controls. One-year and two-year
longitudinal studies of neuropsychological impairments in EOS found no change in the
magnitude of deficits in patients with EOS (Cervellione, Burdick, Cottone, Rhinewine,
& Kumra, 2007; Juuhl-Langseth, Holmen, Thormodsen, Oie, & Rund, 2014; Teigset
et al., 2018). In two studies featuring four-year and 13-year follow-up intervals, there
was a decline in verbal memory, attention and processing speed in individuals with
EOS (Frangou, Hadjulis, & Vourdas, 2008; Oie et al., 2011; Wozniak, Block, White,
Jensen, & Schulz, 2008). To sum up, both children and adolescents with ASD and EOS
have been found to have executive and memory impairments compared to TD controls.
One-year and two-year longitudinal studies indicate working memory delay in children
and adolescents with ASD compared to no delay in children and adolescents with EOS.
However, studies with longer follow-up intervals have found neuropsychological delay
in young persons with EOS as well.
Only a few studies have compared children or adolescents with EOS directly with ASD
on neuropsychological performance (Asarnow, Tanguay, Bott, & Freeman, 1987; Schnei-
der & Asarnow, 1987; Waris et al., 2016). In an early work of Schneider and Asarnow
(1987), they found similar levels of impairment in processing speed and executive func-
tioning in children with EOS and ASD. However, children with ASD had significantly
more impairments in verbal functioning as indexed by scores on the verbal comprehen-
sion factor as assessed using WISC-R compared with children with EOS (Asarnow
et al., 1987). Children and adolescents with EOS have been found to have more impaired
visual reasoning skills, working memory and processing speed than children and adoles-
cents with ASD (Asarnow et al., 1987; Waris et al., 2016). Waris et al. (2016) also found
evidence for impaired visual processing in children and adolescents with EOS compared to
young patients with ASD. Thus, there are few comparison studies and some inconsistent
findings regarding neuropsychological functioning in children and adolescents with ASD
compared with EOS. Earlier research is also hampered by small sample sizes, a focus on
single domains of neuropsychological functioning (i.e. IQ level), and an absence of a typi-
cally developing control group. Further, to the best of our knowledge, no longitudinal
studies have directly compared the development of neuropsychological functioning in
adolescents with ASD to that of adolescents with EOS.
As earlier described, although the disorders are distinct, they share central clinical fea-
tures. It can therefore be difficult to differentiate diagnoses and thereby provide optimal
treatment. This is especially important in children and adolescents, as they are in a
period of considerable development of neuropsychological and social functions and
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identity (Blakemore & Choudhury, 2006). Follow-up studies mapping the neuropsycholo-
gical functioning of individuals with ASD or EOS may inform the field regarding salient
cognitive similarities and differences between the disorders. In order to provide the best
possible treatment for individuals with ASD and EOS, there is a need to understand the
unique and shared developmental trajectories in the two developmental disorders. The
current two-year follow-up study assesses a wider range of neuropsychological domains
compared to other studies in a relatively larger sample of adolescents with ASD or EOS.
The present study
The main aim of the current study is to compare neuropsychological functioning at base-
line (T1) and after two years (T2) in adolescents with ASD (IQ > 70) compared with ado-
lescents with EOS. Our research questions are: Are there any differences in
neuropsychological functioning between adolescents with ASD and adolescents with
EOS at baseline? Is there a difference between the neuropsychological development of
the groups over two years? As there are few comparison studies on neuropsychological




See Table 1 for demographic and clinical characteristics of the participants. In the current
study, data from two different research projects were merged. One of the earlier studies
had focussed on adolescents with ASD compared to TD controls; another study focused
on adolescents with EOS compared to TD controls. In the current study, results from
the ASD study were directly compared with results from the EOS study.
Table 1. Demographic and clinical characteristics: means and standard deviations by group and
assessment time.
Variable
Baseline (T1) Follow-up (T2)
ASD (n = 21) EOS (n = 22) ASD (n = 20) EOS (n = 17)
Sex (male/female) 20/1 11/11 19/1 7/10
Age 14.4 (1.5) 15.2 (1.5) 16.5 (1.5) 17.6 (1.7)
Mother’s education (yrs) 12.9 (2.6) 13.0 (3.0) – –
FSIQa,d 94.7 (17.1) 99.8 (14.8) 94.8 (16.4) –
PIQb,d 95.0 (22.8) 101.8 (14.8) 99.4 (15.9) –
VIQc,d 91.0 (19.0) 97.1 (15.7) 94.7 (17.6) –
CGAS/GAFe 49.1 (11.4) 48.5 (15.7) 48.4 (9.9) 60.1 (10.6)
PANSS totalf – 55.1 (11.4) – 50.4 (13.0)
ASSQg 25.8 (8.9) – 21.4 (9.6) –
Note: ASD: Autism Spectrum Disorder; EOS: early-onset schizophrenia.
aFSIQ; full scale IQ. IQ estimated measures from the Wechsler Abbreviated Scale of Intelligence (WASI).
bPIQ; estimated performance intelligence.
cVIQ; estimated verbal intelligence.
dIQ scores from T2 were not available for the EOS group.
eCGAS/GAF; Children’s Global Assessment Scale/Global Assessment of Functioning.
fPANSS; Positive and Negative Syndrome Scale (n = 24).
gASSQ; Autism Spectrum Screening Questionnaire.
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The ASD group consisted of 38 participants and the EOS group of 27 participants. In
order to obtain similar age distributions in the groups (12–18 years), the ASD group was
restricted to 21 adolescents with ASD (20 males/1 female) and the EOS group to 22 (11
males/11 females) at baseline (T1). The ASD group was recruited in 2009–2010 from
all Child and Adolescent Mental Health Centers in Innlandet Hospital Trust (CAMHC)
in two Norwegian counties (Hedmark and Oppland) with a county-wide population of
375,000 people. In Norway, children with autism without intellectual disability are most
often referred to CAMHC, whereas children with ASD and intellectual disability are
referred to child habilitation centres. Thus, only children with ASD without intellectual
disability were included in the study. See Andersen et al. (Andersen, Skogli, Hovik,
Egeland, & Oie, 2015; Andersen, Skogli, Hovik, Geurts, et al., 2015) for a more detailed
description of the cohort. Two individuals in the ASD group had comorbid depression
and one had comorbid Attention Deficit Hyperactivity Disorder (ADHD). Participants
with ASD were assessed with separate interviews of children and their parents using the
Schedule for Affective Disorders and Schizophrenia for School Age Children/Present
and Lifetime version-2009 (K-SADS-PL) (Kaufman et al., 1997). The K-SADS-PL is a
semi-structured diagnostic interview designed to correspond to the Diagnostic and Stat-
istical Manual for Mental Disorders fourth edition (DSM-IV; American Psychiatric
Association, 2000). The K-SADS-PL was supplemented with information from the
Autism Spectrum Screening Questionnaire (ASSQ; Ehlers & Gillberg, 1993). Clinical sig-
nificance was assessed by applying normative data from the ASSQ (Ehlers, Gillberg, &
Wing, 1999). The interviewers were experienced clinicians and were trained to high
levels of interrater reliability for diagnostic assessment. In addition, the diagnostic evalu-
ation was supplemented with information from the Child Behavior Checklist/6–18 (CBCL
6–18; Achenbach & Rescorla, 2001), which was completed by both parents. Diagnosis was
confirmed if DSM-IV criteria were met through an exhaustive evaluation of the K-SADS-
PL screening interview, K-SADS-PL diagnostic interview for autism, and parent reports
together with information from teachers concerning academic and social functioning. Dis-
agreements regarding diagnosis were discussed in meetings with all the clinicians present
to arrive at a “best estimate”DSM-IV (American Psychiatric Association, 2000) consensus
diagnosis. At baseline, nineteen in the ASD group were diagnosed with Asperger’s syn-
drome and two with pervasive developmental disorder—not otherwise specified (PDD-
NOS). One child was using psychostimulants (methylphenidate), but the medication
was discontinued 24 h prior to assessment.
Follow-up (T2) assessment of the ASD group was conducted two years following base-
line (T1) assessment. The reassessment procedures at T2 were similar to T1. All ASD diag-
noses were confirmed. One participant in the ASD group refused to participate at T2. At
T2, two participants in the ASD group were using antipsychotic medication and four were
using psychostimulants (methylphenidate). The psychostimulants were discontinued 24 h
prior to assessment.
The results for the EOS group were collected from an earlier broader research project at
the University of Oslo, Norway, on adolescents aged 12–18 years with early onset psycho-
tic disorders and TD controls (Holmen, Juuhl-Langseth, Thormodsen, Melle, & Rund,
2010; Juuhl-Langseth et al., 2012; Thormodsen, Juuhl-Langseth, Holmen, & Rund,
2012). This study had tested patients with EOS and TD controls on a neuropsychological
test battery at baseline (between 2005 and 2008), after one year and after two years. In the
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current study, we used the results from the baseline study (T1) and the two-year follow-up
(T2). At baseline (T1), a total of 22 patients were included in this study (11 males/11
females). The patients were recruited from multiple hospitals and outpatient units in
Oslo and Eastern Norway. Patients were included if they were between 12 and 18 years
of age and met the DSM-IV (American Psychiatric Association, 2000) criteria for a
broad schizophrenia-spectrum disorder (schizophrenia, schizophreniform disorder, schi-
zoaffective disorder, brief psychotic disorder and psychosis not otherwise specified
[NOS]). Patients were diagnosed using the Structured Clinical Interview for DSM-IV
Axis I Disorders (SCID-I), modules A–D. Comorbid diagnoses were not registered in
the EOS group. The mean inter-rater reliability (kappa) for the SCID was 0.77. Thirteen
patients were on antipsychotic medication and one was on an antidepressant. Seventeen
participants consented to further participation after two years. Procedures for re-assess-
ment at follow-up were the same as for baseline. Seven patients in the EOS group were
medicated with antipsychotics at the two-year follow-up.
All participants in both projects were offered standard (“treatment as usual”) psycho-
logical and/or medical treatment in the period between inclusion and reassessment. The
exclusion criteria for the ASD and the EOS groups were any neurological disease and
an IQ estimate below 70.
There were significantly fewer girls at T1 (p = .001) and T2 (p < .001) in the ASD group
compared to the EOS group. The differences between groups on the Children’s Global
Assessment Scale (CGAS)/Global Assessment of Functioning-Split version (Split-GAF)
and on other demographic characteristics were not significant at T1 (Table 2).
Measure of psychotic symptoms
Psychotic symptoms were assessed in the EOS group using the Positive and Negative Syn-
drome Scale (PANSS; Kay, Fiszbein, & Opler, 1987). The PANSS evaluates a multidimen-
sional array of symptoms (e.g., positive, negative, depressive), and involves the use of data
from patient reports, caregiver reports, and clinical observations (Kay et al., 1987; Opler,
Yavorsky, & Daniel, 2017). Higher scores indicate more problems.
Table 2. Demographic characteristics: chi-square and univariate comparisons (Bonferroni corrected for
multiple comparisons .05/6 = .008).
Variable
Baseline (T1) Follow-up (T2)
Group comparisons Group comparisons
Chi-sq./ F p Chi-sq./ F p
Sex (male/female) 10.9 .001 12.7 <.001
Age (1,41) 3.26 NS. (1,35) 4.72 NS.
Mother’s education (yrs) (1,40) .027 NS. – –
FSIQa,b (1,41) 1.10 NS. – –
PIQc (1,41) 1.39 NS. – –
VIQd (1,41) 1.32 NS. – –
CGAS/GAFe (1,41) .027 NS. (1,33) 11.4 .002
Note: ASD: Autism Spectrum Disorder; EOS: early-onset schizophrenia.
aFSIQ: full scale IQ. IQ estimated measures from the Wechsler Abbreviated Scale of Intelligence (WASI).
bIQ scores from T2 were not available for the EOS group.
cPIQ: estimated performance intelligence.
dVIQ: estimated verbal intelligence.
eCGAS/GAF: Children’s Global Assessment Scale/Global Assessment of Functioning.
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Measure of ASD symptoms
The Autism Spectrum Screening Questionnaire (ASSQ; Ehlers & Gillberg, 1993) was
administered to measure ASD symptoms in the ASD group. The ASSQ is a 27-item check-
list for assessing symptoms characteristic of Asperger’s Syndrome or high-functioning
autism spectrum disorders. In the current study, a parent rating was used. The items
encompass social interaction problems, communication problems and problems with
restricted and repetitive behaviours (Ehlers et al., 1999). Higher scores indicate more
problems.
Global level-of-functioning measure
Global level of functioning in the ASD group was assessed using the CGAS (Shaffer et al.,
1983) and functioning in the EOS group was assessed using the Split-GAF (Pedersen,
Hagtvet, & Karterud, 2007). The CGAS is an adaptation of the GAF-F for adults.
Higher scores on the CGAS or the GAF-F indicate a better level of functioning.
Measures of neuropsychological functioning
Verbal learning and memory
The Hopkins Verbal Learning Test—Revised (HVLT-R) total learning, delayed recall, and
recognition score were used (Brandt & Benedict, 2001). Higher raw scores indicate better
performance.
Visual learning and memory
The Brief Visuospatial Memory Test—Revised (BVMT-R) total learning, delayed recall,
and recognition were used (Benedict, 1997). Higher raw scores indicate better
performance.
Verbal processing speed
The Color-Word Interference Test from the D-KEFS battery (Delis, Kaplan, & Kramer,
2001) runs the following two baseline conditions: colour naming (CW1) of colour
patches, and word reading (CW2) of colour-words printed in black. We measured
overall time used to complete the task. Higher raw scores indicate difficulties with the task.
Inhibition
The Color-Word Interference Test from the D-KEFS battery, Condition 3 (CW3; Delis
et al., 2001). The participant must inhibit an overlearned verbal response when naming
the dissonant ink colours in which the words are printed. We measured overall time
used to complete the task. Higher raw scores indicate difficulties with the task.
Mental flexibility
The Color-Word Interference test from the D-KEFS battery, Condition 4 (CW4; Delis
et al., 2001). In CW4, the participant must switch between reading printed words
written in different colours and name the dissonant ink colour. We measured overall
time used to complete the task. Higher raw scores indicate poorer performance.
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Estimated verbal and non-verbal intelligence
Because the participants in the projects underwent a large test battery, it was important to
limit the number of tests in order to make it more attractive for them to participate in the
follow-up study. To estimate full-scale IQ, the Wechsler Abbreviated Scale of Intelligence
was administered (WASI; Wechsler, 2007). WASI is the short version of the Wechsler’s
intelligence tests. A Norwegian study found almost identical Total IQ on WASI and
WAIS / WISC-R in a mixed clinical group sample (Bosnes, 2009). WASI provides a
reliable, brief measure of intelligence in clinical, educational and research settings.
WASI is a battery of four subtests: Vocabulary, Block Design, Similarities, and Matrix
Reasoning. The four subtests comprise an estimate of Full-Scale IQ (FSIQ). The Vocabu-
lary and Similarities subtests are combined to form an estimate of Verbal IQ (VIQ), and
the Block Design and Matrix Reasoning subtests yield an estimate of Performance IQ
(PIQ) score. Since we only had WASI scores from T1 for the EOS group on this
measure, we could only compare the groups on this measure at baseline.
Statistical analyses
Data analyses were performed with IBM SPSS Statistics, version 25 (IBM, SPSS, Inc.,
Chicago, IL). Significant results are reported at p < .05 level. Demographic characteristics
were investigated using the Chi-squared test for independence (gender) and independent
measures T-test (age, mother’s education, IQ and CGAS/GAF). Analyses of variance
(ANOVA) was used to investigate differences between the two groups at baseline (T1).
Mixed between-within subjects’ ANOVAs (mixed ANOVA) were conducted to assess
the interaction between diagnosis and time for all neuropsychological measures. We ran
separate mixed ANOVAs controlling for the effect of antipsychotic medication at baseline.
Due to multiple comparisons, Bonferroni corrections were used to control for chance
findings. Since we did not have standard scores for all measures, we used the raw
scores when comparing performance between the groups.
Ethical approval
Both research projects received advance approval by the Regional Committee for Medical
Research Ethics in Eastern Norway (REK-Øst), and by the Privacy protection ombudsman
for research at Innlandet Hospital Trust or Norwegian Data Inspectorate. We also received
ethical approval to merge the two datasets form the different ASD and EOS studies.
Consent was given in accordance with the ethical principles specified in the Declaration
of Helsinki.
Results
There was no significant effect of group on the neuropsychological measures. There was a
significant effect of time for both groups with improved results on verbal processing speed
(CW1) (p < .001), inhibition (CW3) (p < .001), mental flexibility (CW4) (p < .001) (see
Table 3). There was a significant effect of time for both groups with decreased results
on verbal recognition (HVLT)(p = .004). However, both groups achieved near
maximum scores at both time points. They did not improve significantly over the two
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Table 3. Results on CW 1–4 (completion time in sec.), HVLT (raw scores) and BVMT (raw scores) at T1 and T2, WASI comprehension and similarities at T1 (T-scores):
means and standard deviations within the ASD and the EOS groups, and results (Bonferroni corrected for multiple comparisons .05/12 = .004) from Mixed Model
ANOVA and ANOVA.
Variable
ASD (n = 20) EOS (n = 17) Group Time Time × Group
T1 T2 T1 T2 F p F p F p h2p
CW1a 45.2 (12.6) 38.5 (9.3) 36.9 (7.8) 32.2 (7.2) (1,34) 6.00 NS. 22.1 <.001 .675 NS. .019
CW2 30.1 (6.7) 28.0 (6.4) 27.1 (7.7) 24.3 (6.5) (1,34) 2.54 NS. 7.09 NS. .166 NS. .005
CW3 85.6 (25.5) 69.2 (21.8) 64.6 (18.6) 56.1 (18.7) (1,34) 7.11 NS: 14.4 .001 1.44 NS. .041
CW4 91.1 (25.7) 71.0 (13.3) 72.2 (22.4) 62.6 (22.8) (1,34) 4.60 NS. 19.3 <.001 2.45 NS. .067
HVLT learningb 22.7 (6.3) 20.6 (4.3) 24.8 (5.4) 23.9 (5.9) (1,35) 2.78 NS. 3.16 NS. .501 NS. .014
HVLT delayed recall 7.6 (2.7) 7.2 (2.6) 8.4 (2.9) 7.4 (2.5) (1,35) .482 NS. 2.40 NS. .461 NS. .016
HVLT recognition 11.5 (.6) 11.1 (1.1) 11.5 (1.1) 10.6 (1.3) (1,35) .581 NS. 9.69 .004 1.37 NS. .038
BVMT learningc 22.8 (8.4) 25.3 (9.7) 25.4 (8.1) 26.2 (6.2) (1,33) .451 NS. 1.94 NS. .492 NS. .015
BVMT delayed recall 9.5 (3.3) 10.1 (2.9) 10.1 (2.2) 9.9 (2.3) (1,33) .065 NS. .445 NS. 1.05 NS. .031
BVMT recognition 5.9 (.32) 6.7 (2.5) 5.8 (.39) 6.0 (.0) (1,33) 1.53 NS. 2.86 NS. 1.21 NS. .035
WASI comprehensiond 43.9 (8.9) 47.2 (10.9) (1,41) 1.23 NS.
WASI similarities 47.7 (11.8) 48.5 (11.7) (1,41) .054 NS.
Note: aCW1-4: Delis-Kaplan Colour-word interference test conditions 1, 2, 3 and 4 time in seconds.
bHVLT: Hopkins Verbal Learning Test—Revised.
cBVMT: Brief Visuospatial Memory Test—Revised.















years on verbal learning, verbal delayed recall, visual learning, visual delayed recall or rec-
ognition. There was no significant interaction effect between time and group on the neu-
ropsychological measures. Analyses conducted controlling for the use of antipsychotics
revealed no significant group differences on the neuropsychological measures. Thus, no
group differences were found when running analyses controlling for or not controlling
for potential medication effects.
Earlier results from the previous ASD study have shown that the individuals displayed
stable deficits compared to TD controls on most measures at T1 and T2. The only excep-
tion was performance after two years on verbal working memory, where the ASD group
showed a decline in results compared to the TD adolescents (Andersen et al., 2013; Ander-
sen, Skogli, Hovik, Geurts, et al., 2015). Earlier results on the EOS group’s neuropsycho-
logical performance indicate a stable deficit at T1 and T2 on most measures compared to
TD individuals (Juuhl-Langseth et al., 2012).
Discussion
The main finding of the current study is that there were similar levels of neuropsycholo-
gical impairment in the adolescents with ASD or EOS across groups and over time. Our
cross-sectional results are consistent with the results of Schneider and Asarnow (1987).
Our results support the hypothesis of shared neuropsychological pathways influencing
cognitive development in these two neurodevelopmental disorders and support the
notion of an autism-schizophrenia continuum (King & Lord, 2011). However, different
neural substrates may be responsible for similar cognitive impairments in EOS and
ASD. One study found two distinct areas involved in the brain pathophysiology relevant
to cognitive processing in patients with ASD and schizophrenia (Hirata et al., 2018). If
different neural substrates cause similar cognitive endophenotypes, then this may indicate
an important direction for future research, especially when considering cognitive remedia-
tion and medical treatment in these two disorders.
Asarnow et al. (1987) and Waris et al. (2016) found that their EOS groups showed sig-
nificantly lower performance in processing speed compared with their ASD groups. We
found no significant differences between the ASD and the EOS groups in processing
speed. An explanation for the difference in results in our study compared with earlier
studies may be that the neuropsychological tests used in earlier studies were not the
same as in our study. The earlier studies used tests that required motor processing
speed, whereas the test used in our study taxed verbal processing speed. Another expla-
nation for our results might be that the processing speed tasks applied in our study
were too simple, and thus were not able to differentiate between the two groups. The
manipulative load is relatively low in the Color-Word Interference Test conditions 1
and 2. In their study examining working memory function, Conklin, Luciana, Hooper,
and Yarger (2007) found that low central executive processing matures prior to more
complex ones requiring cognitive manipulation. This might suggest that tasks applying
more basic processing requirements were too simple to detect subtle neuropsychological
differences between the groups compared to using tasks requiring more cognitive effort.
Asarnow et al. (1987) found that children with ASD had significantly more impair-
ments in verbal functioning compared with children with EOS. Many of the children
with ASD in their study, however, had deficits in language development and/or peculiar
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speech patterns, which is in contrast to our study in which none in our ASD group had any
delayed language development issues. Further, the participants in the Asarnow et al.
(1987) study were younger than our participants. These factors may explain the differences
in results between our studies.
Waris et al. (2016) also found evidence of impaired visual processing measured with all
of the visual cognition subtests from WISC-III in EOS compared with children and ado-
lescents with ASD. In our study, two performance IQ tests were used from the WASI, and
we used the BVMT to investigate visual cognition. The use of different outcome tests for
visual cognition in the two studies means that caution must be exercised when comparing
the results in this domain.
We found no differences between the groups in the two-year longitudinal course of the
neuropsychological functions. As far as we know, no other studies have investigated neu-
ropsychological similarities or differences over such a long period of time during a critical
developmental period in adolescents with ASD and EOS. More longitudinal studies com-
paring neuropsychological abilities across the two disorders are needed.
Strengths and limitations of the study
A strength of our study is that the sample size was larger than other comparison studies
regarding neuropsychological functioning in adolescents with EOS or ASD. Still, small
sample size may represent a weakness in this study. A small sample, however, is a
common problem in longitudinal studies of EOS, due to the rarity of the illness and the
challenges of long-term follow-up of this population (Cervellione et al., 2007). Other
strengths of this study are the use of a neuropsychological test battery and the longitudinal
design. However, the neuropsychological test battery was relatively brief and a broader
neuropsychological testing could have been even more helpful to understand the cognitive
functioning of the two groups. Further, the lack of WASI data for the EOS group at T2 is a
limitation. Due to the lack of detailed information regarding interventions given during
the follow-up period, we were not able to control for interventions. Further, some EOS
patients were assessed without antipsychotic medication at T2 and with medication at
T1. In addition, two participants in the ASD group were using antipsychotic medication
at T2 but not at T1. This may have confounded the course of cognition with potential
medication effects. Another limitation may be the lack of having used clinical diagnostic
observation tools such as the Autism Diagnostic Interview—Revised (ADI-R) or Autism
Diagnostic Observation Scale (ADOS) for the ASD group. Although neuropsychological
functioning matures considerably in the adolescent years, it is possible that two years is
too short a period to detect any differing trajectories in neuropsychological development
between the groups in the study. Future research should therefore include a longer follow-
up period. Further, a one-year follow-up in both groups would have allowed us to model
the data with more complex statistical models that could have provided a clearer picture of
cognitive change over time.
Clinical implications
Our findings provide support for the position that there are close similarities in neurop-
sychological deficit patterns between ASD and EOS. A possible clinical implication is that
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measures of neuropsychological functioning cannot differentiate EOS from ASD in clini-
cal practice. Because of similarities in symptomatology and cognitive deficits in ASD and
EOS, clinicians may be less likely to detect the co-occurrence or continuity of autism and
schizophrenia conditions. Thus, if a child has a diagnosis of ASD and develops schizo-
phrenia later on, clinicians may be less likely to diagnose it (Pina-Camacho, Parellada,
& Kyriakopoulos, 2016). A recent study found transdiagnostic validity of the Measure-
ment and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Con-
sensus Cognitive Battery (MCCB) across the autism-schizophrenia spectrum in adults
(Kuo, Wojtalik, Mesholam-Gately, Keshavan, & Eack, 2019). The study highlights
MCCB’s applicability to ASD and supports its utility for standardising treatment evalu-
ations of cognitive outcomes across the autism-schizophrenia spectrum. The data from
our research project on adolescents with ASD and EOS provide support for the position
that there are close similarities in neuropsychological deficit patterns between ASD and
EOS and that standardised assessment tools can be valid and reliable for use in both popu-
lations. EOS and ASD are associated with educational failure, occupational impairment
and reduced quality of life (Baxter et al., 2015; Woolfenden, Sarkozy, Ridley, Coory, &
Williams, 2012). Our findings identifying a shared pattern of neuropsychological impair-
ment in individuals with ASD and EOS offers possible common ground for early cognitive
remediation efforts for these two devastating developmental disorders.
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